...
首页> 外文期刊>Diabetes care >Pancreas Transplant Alone: A procedure coming of age.
【24h】

Pancreas Transplant Alone: A procedure coming of age.

机译:胰腺移植单独:年龄的过程。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The goal of this review is to highlight the significant improvements, over the past four decades, in outcomes after a pancreas transplant alone (PTA) in patients with brittle diabetes and recurrent episodes of hypoglycemia and/or hypoglycemic unawareness. A successful PTA-in contrast to intensive insulin regimens and insulin pumps-restores normoglycemia without the risk of hypoglycemia and prevents, halts, or reverses the development or progression of secondary diabetes complications. In this International Pancreas Transplant Registry (IPTR) analysis, we reviewed the records of 1,929 PTA recipients from December 1966 to December 2011. We computed graft survival rates according to the Kaplan-Meier method and used uni- and multivariate analyses. In the most recent era (January 2007-December 2011), patient survival rates were >95% at 1 year posttransplant and >90% at 5 years. Graft survival rates with tacrolimus-based maintenance therapy were 86% at 1 year and 69% at 3 years and with sirolimus, 94 and 84%. Graft survival rates have significantly improved owing to marked decreases in technical and immunologic graft failure rates (P < 0.05). As a result, the need for a subsequent kidney transplant has significantly decreased, over time, to only 6% at 5 years. With patient survival rates of almost 100% and graft survival rates of up to 94% at 1 year, a PTA is now a highly successful long-term option. It should be considered in nonuremic patients with brittle diabetes in order to achieve normoglycemia, to avoid hypoglycemia, and to prevent the development or progression of secondary diabetes complications.
机译:本综述的目标是突出超过四十年的显着改善,在胰腺移植(PTA)易患糖尿病患者的胰腺移植和经复血分症和/或低血糖性发作的反复发作后的结果。与强化胰岛素方案和胰岛素泵恢复的成功PTA - 没有低血糖的风险,阻止,停止或逆转次级糖尿病并发症的发育或进展的常规血糖瘤。在这次国际胰腺移植登记处(IPTR)分析中,我们从1966年12月到2011年12月审查了1,929个PTA收件人的记录。我们根据KAPLAN-MEIER方法计算了移植物生存率,并使用了UNI-和多变量分析。在最近的一次ERA(2011年1月至2011年1月)中,患者存活率在1年后持续物品率为95%,5年后> 90%。与达克兰司的维持治疗的接枝存活率为86%,持续86%,3年,西罗莫司,94%和84%。由于技术和免疫接枝衰竭率显着降低,移植物存活率显着提高(P <0.05)。结果,随着时间的推移,对随后的肾移植的需求显着降低到5年的6%。患者存活率几乎100%,接枝存活率在1年内高达94%,现在是一个高度成功的长期选择。在非血糖患者中应该考虑脆性糖尿病,以达到正常血糖,以避免低血糖症,并防止第二糖尿病并发症的开发或进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号